Connection
Stephen Waldo to Purinergic P2Y Receptor Antagonists
This is a "connection" page, showing publications Stephen Waldo has written about Purinergic P2Y Receptor Antagonists.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.242 |
|
|
|
-
Aijaz B, Glorioso TJ, Butala N, Waldo SW. Temporal trends and hospital variation in the use of P2Y12 inhibitors among patients undergoing percutaneous coronary intervention: Insights from the VA CART program. Catheter Cardiovasc Interv. 2023 09; 102(3):503-504.
Score: 0.203
-
Xie JX, Gunzburger EC, Kaun L, Plomondon ME, Bar?n AE, Waldo SW, Virani SS, Maddox TM, Mavromatis K. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e005455.
Score: 0.039